Celecoxib effects on COVID-19 patients
- Conditions
- COVID-19.COVID-19U07.1
- Registration Number
- IRCT20200907048644N1
- Lead Sponsor
- Zahedan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Subjects with COVID-19 in the second phase of the disease
Shortness of breath, chest pain with or without fever equal to or greater than 38 'C
Blood oxygen saturation (SpO2) between 90-93%
Adult patients with COVID-19 with moderate pulmonary involvement and hospitalized in the general ward who have been diagnosed and confirmed with coronavirus by conventional diagnostic methods such as sequencing or qRT-PCR and CT (within 48 hours of admission)
Age range of patients between 18-65 years
Existence of pneumonia in lung CT scan with involvement of maximum 3 or 4 lung lobes or less than one third of the volume of each lobe or infection of one or two lobes with larger area
Patients informed consent
Patients under 18 or over 65 years old
Patients with severe and advanced disease are admitted to the intensive care unit
Participate in another clinical trial
Shock and critical illness (requires ventilator and organ failure)
Patients with organ dysfunction such as renal failure and liver damage, patients with asthma
Taking certain medications such as furosemide or Lasex, lithium, ACE2 inhibitors
Pregnancy
People with medical history such as high blood pressure, autoimmune diseases and ..
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ung function (Pulmonary infiltration, GGO, Edema). Timepoint: Every week. Method of measurement: CT Scan.;Respiratory Rate, SpO2, PaO2/FiO2. Timepoint: Every day. Method of measurement: Physical examination.;Body Temperature. Timepoint: Every day. Method of measurement: Thermometer.
- Secondary Outcome Measures
Name Time Method